Expertise in
7
conditions

Min-hee S. Ryu

Seoul, KR 
Expertise in
7
conditions
Seoul, KR 
OverviewLocationsClinical Research

Overview

Min-hee Ryu practices in Seoul, Republic of Korea. Ryu is highly rated in 7 conditions, according to our data. Their top areas of expertise are Stomach Cancer, Gastroesophageal Junction Cancer, Gastrointestinal Stromal Tumor, Gastrectomy, and Stent Placement.

Their clinical research consists of co-authoring 311 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

Seoul, Republic of Korea
Other Locations
Daegu, Republic of Korea
Ulsan, Republic of Korea
Kwonoh Park, Gyeongsangnam Do 50612, Busan, Republic of Korea
Jeonju, Republic of Korea

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel in Patients With Metastatic Gastric Cancer After Failure of First-line Chemotherapy, Phase Ib/II
Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel in Patients With Metastatic Gastric Cancer After Failure of First-line Chemotherapy, Phase Ib/II
Enrollment Status: Completed
Publish Date: February 28, 2024
Intervention Type: Drug
Study Drug: Durvalumab+Tremelimumab+Paclitaxel
Study Phase: Phase 1/Phase 2
Randomized Phase 2 Study of Intermittent vs Continuous Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors (GISTs)
Randomized Phase 2 Study of Intermittent vs Continuous Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors (GISTs)
Enrollment Status: Completed
Publish Date: January 04, 2023
Intervention Type: Drug
Study Drug: Imatinib Mesylate
Study Phase: Phase 2
A Phase III Open-label, Multicenter Trial of Maintenance Therapy With Avelumab (MSB0010718C) Versus Continuation of First-line Chemotherapy in Subjects With Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-esophageal Junction
A Phase III Open-label, Multicenter Trial of Maintenance Therapy With Avelumab (MSB0010718C) Versus Continuation of First-line Chemotherapy in Subjects With Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-esophageal Junction
Enrollment Status: Completed
Publish Date: June 09, 2022
Intervention Type: Drug, Other
Study Phase: Phase 3
A Phase I/IIa Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Rivoceranib in Combination With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer
A Phase I/IIa Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Rivoceranib in Combination With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer
Enrollment Status: Terminated
Publish Date: April 11, 2022
Intervention Type: Drug
Study Drugs: Rivoceranib, Paclitaxel
Study Phase: Phase 1/Phase 2
A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) as a Third-line Treatment of Unresectable, Recurrent, or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) as a Third-line Treatment of Unresectable, Recurrent, or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Completed
Publish Date: November 24, 2020
Intervention Type: Drug, Other
Study Phase: Phase 3
View 4 Less Clinical Trials

311 Total Publications

Correction: Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer.
Correction: Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer.
Journal: British journal of cancer
Published: November 11, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ryu's expertise for a condition
ConditionClose
    View All 17 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile